EA201891127A1 - Нуклеиновые кислоты, кодирующие повторяющиеся аминокислотные последовательности с высоким содержанием пролиновых и аланиновых остатков, имеющие нуклеотидные последовательности с низкой повторяемостью - Google Patents

Нуклеиновые кислоты, кодирующие повторяющиеся аминокислотные последовательности с высоким содержанием пролиновых и аланиновых остатков, имеющие нуклеотидные последовательности с низкой повторяемостью

Info

Publication number
EA201891127A1
EA201891127A1 EA201891127A EA201891127A EA201891127A1 EA 201891127 A1 EA201891127 A1 EA 201891127A1 EA 201891127 A EA201891127 A EA 201891127A EA 201891127 A EA201891127 A EA 201891127A EA 201891127 A1 EA201891127 A1 EA 201891127A1
Authority
EA
Eurasian Patent Office
Prior art keywords
nucleic acid
nucleotide sequence
amino acid
proline
low repeatability
Prior art date
Application number
EA201891127A
Other languages
English (en)
Inventor
Ули Биндер
Стефан Ахац
Арне Скерра
Original Assignee
ИксЭль-ПРОТЕИН ГМБХ
Технише Университет Мюнхен
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ИксЭль-ПРОТЕИН ГМБХ, Технише Университет Мюнхен filed Critical ИксЭль-ПРОТЕИН ГМБХ
Publication of EA201891127A1 publication Critical patent/EA201891127A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/165—Mathematical modelling, e.g. logarithm, ratio

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Изобретение относится к молекуле нуклеиновой кислоты, содержащей нуклеотидную последовательность с низкой повторяемостью, кодирующую повторяющуюся аминокислотную последовательность с высоким содержанием пролина/аланина. Кодируемый полипептид содержит повторяющуюся аминокислотную последовательность, образующую случайный клубок. Молекула нуклеиновой кислоты, содержащая указанные нуклеотидные последовательности с низкой повторяемостью, может дополнительно содержать нуклеотидную последовательность, кодирующую биологически или фармакологически активный белок. Кроме того, согласно настоящему изобретению предложены средства и способы отбора, позволяющие идентифицировать указанную молекулу нуклеиновой кислоты, содержащую указанную нуклеотидную последовательность с низкой повторяемостью. Настоящее изобретение также относится к способу получения указанных молекул нуклеиновых кислот. Кроме того, здесь предложены способы получения кодируемого полипептида или конъюгатов лекарственных средств с кодируемым полипептидом с использованием предложенных здесь молекул нуклеиновых кислот. Конъюгат лекарственного средства может содержать биологически или фармакологически активный белок или низкомолекулярное лекарственное средство. Кроме того, здесь предложены векторы и хозяева, содержащие такие молекулы нуклеиновых кислот.
EA201891127A 2015-12-22 2016-12-22 Нуклеиновые кислоты, кодирующие повторяющиеся аминокислотные последовательности с высоким содержанием пролиновых и аланиновых остатков, имеющие нуклеотидные последовательности с низкой повторяемостью EA201891127A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15202093 2015-12-22
PCT/EP2016/082407 WO2017109087A1 (en) 2015-12-22 2016-12-22 Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences

Publications (1)

Publication Number Publication Date
EA201891127A1 true EA201891127A1 (ru) 2019-01-31

Family

ID=55129435

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891127A EA201891127A1 (ru) 2015-12-22 2016-12-22 Нуклеиновые кислоты, кодирующие повторяющиеся аминокислотные последовательности с высоким содержанием пролиновых и аланиновых остатков, имеющие нуклеотидные последовательности с низкой повторяемостью

Country Status (19)

Country Link
US (1) US11401305B2 (ru)
EP (2) EP3919623A1 (ru)
JP (1) JP7065772B2 (ru)
KR (1) KR102654180B1 (ru)
CN (1) CN109153996B (ru)
AU (1) AU2016378646B2 (ru)
BR (1) BR112018012784A2 (ru)
CA (1) CA3005115A1 (ru)
DK (1) DK3394266T3 (ru)
EA (1) EA201891127A1 (ru)
ES (1) ES2877539T3 (ru)
HU (1) HUE055267T2 (ru)
IL (1) IL259352B (ru)
LT (1) LT3394266T (ru)
MX (1) MX2018007680A (ru)
PL (1) PL3394266T3 (ru)
SG (1) SG11201803958WA (ru)
SI (1) SI3394266T1 (ru)
WO (1) WO2017109087A1 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9725710B2 (en) 2014-01-08 2017-08-08 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US10174302B1 (en) 2017-06-21 2019-01-08 Xl-Protein Gmbh Modified L-asparaginase
CN111406071B (zh) * 2017-11-16 2024-01-16 成都硕德药业有限公司 Pas化的vegfr/pdgfr融合蛋白及其在治疗中的用途
WO2019096226A1 (en) * 2017-11-16 2019-05-23 Chengdu Easton Biopharmaceuticals Co., Ltd. Pasylated vegfr/pdgfr fusion proteins and their use in therapy
KR102439221B1 (ko) 2017-12-14 2022-09-01 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
WO2019165345A1 (en) * 2018-02-23 2019-08-29 Innovate Biopharmaceuticals, Inc. Compositions and methods for treating or preventing intestinal paracellular permeability
KR102209198B1 (ko) * 2019-04-02 2021-02-02 주식회사 바이오앱 식물에서의 발현이 최적화된 재조합 이리신 유전자 및 이를 이용한 재조합 이리신 단백질의 생산 방법
CN110038120B (zh) * 2019-04-02 2022-12-23 河南师范大学 豹蛙抗瘤酶融合蛋白作为治疗肿瘤药物的应用
US20200327961A1 (en) * 2019-04-15 2020-10-15 Bruker Daltonik Gmbh Methods for determining isomeric amino acid residues of proteins and peptides
WO2020227341A1 (en) * 2019-05-06 2020-11-12 9 Meters Biopharma, Inc. Compositions and methods for treating sjogren's syndrome
CA3200238A1 (en) 2020-12-22 2022-06-30 Jonas SCHILZ Antibodies specific for structurally disordered sequences
CN113340864B (zh) * 2021-06-07 2023-04-07 郑州轻工业大学 基于mef效应二次放大ins信号的适体传感器及其制备方法和应用
CN114470170B (zh) * 2022-02-22 2023-09-19 广州新济药业科技有限公司 一种司美格鲁肽可溶性微针组合物及其制备方法
WO2024042236A1 (en) 2022-08-26 2024-02-29 Ethris Gmbh Stable lipid or lipidoid nanoparticle suspensions
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
WO2024124142A2 (en) * 2022-12-08 2024-06-13 Insmed Incorporated Uricase conjugates and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5910488A (en) 1993-06-07 1999-06-08 Vical Incorporated Plasmids suitable for gene therapy
JPH11509088A (ja) 1995-06-23 1999-08-17 プレジデント アンド フェローズ オブ ハーバード カレッジ 血管内皮増殖因子受容体をコードする遺伝子の転写調節
US7378506B2 (en) 1997-07-21 2008-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US20060252120A1 (en) 2003-05-09 2006-11-09 Kieliszewski Marcia J Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
WO2007142954A2 (en) 2006-05-30 2007-12-13 Dow Global Technologies Inc. Codon optimization method
DK2369005T3 (da) 2007-06-21 2013-06-24 Univ Muenchen Tech Biologisk aktive proteiner med forøget stabilitet in vivo og/eller in vitro
EP2571510B1 (en) 2010-05-21 2018-08-08 XL-protein GmbH Biosynthetic proline/alanine random coil polypeptides and their uses
ES2704237T3 (es) 2014-03-05 2019-03-15 Merz Pharma Gmbh & Co Kgaa Nuevas neurotoxinas clostridiales recombinantes con un aumento de la duración del efecto
US10174302B1 (en) 2017-06-21 2019-01-08 Xl-Protein Gmbh Modified L-asparaginase
EP3418383A1 (en) 2017-06-21 2018-12-26 XL-protein GmbH Modified l-asparaginase
EP3641827A1 (en) 2017-06-21 2020-04-29 XL-protein GmbH Conjugates of protein drugs and p/a peptides
CA3068100A1 (en) 2017-06-21 2018-12-27 Jazz Pharmaceuticals Ireland Limited Modified l-asparaginase
WO2019096226A1 (en) 2017-11-16 2019-05-23 Chengdu Easton Biopharmaceuticals Co., Ltd. Pasylated vegfr/pdgfr fusion proteins and their use in therapy

Also Published As

Publication number Publication date
CA3005115A1 (en) 2017-06-29
US11401305B2 (en) 2022-08-02
KR102654180B1 (ko) 2024-04-04
IL259352A (en) 2018-07-31
EP3394266B1 (en) 2021-04-14
SI3394266T1 (sl) 2021-08-31
KR20180088484A (ko) 2018-08-03
AU2016378646A1 (en) 2018-06-14
ES2877539T3 (es) 2021-11-17
CN109153996B (zh) 2022-03-25
US20190010192A1 (en) 2019-01-10
DK3394266T3 (da) 2021-06-07
JP7065772B2 (ja) 2022-05-12
LT3394266T (lt) 2021-08-25
WO2017109087A1 (en) 2017-06-29
CN109153996A (zh) 2019-01-04
PL3394266T3 (pl) 2021-12-13
SG11201803958WA (en) 2018-07-30
BR112018012784A2 (pt) 2019-02-05
AU2016378646B2 (en) 2023-03-09
IL259352B (en) 2022-02-01
EP3919623A1 (en) 2021-12-08
MX2018007680A (es) 2018-11-14
HUE055267T2 (hu) 2021-11-29
NZ742902A (en) 2023-12-22
EP3394266A1 (en) 2018-10-31
JP2019508020A (ja) 2019-03-28

Similar Documents

Publication Publication Date Title
EA201891127A1 (ru) Нуклеиновые кислоты, кодирующие повторяющиеся аминокислотные последовательности с высоким содержанием пролиновых и аланиновых остатков, имеющие нуклеотидные последовательности с низкой повторяемостью
CY1117351T1 (el) Κυτταροδιαπερατοι αναστολεις πεπτιδιων της jnk-σηματοδοτικης πορειας μεταγωγης
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
CY1124518T1 (el) Μεταλλαγες πρωτεϊνης φακελου hiv που σταθεροποιουν το τριμερες
CY1122691T1 (el) Πρωτεϊνες δεσμευσης αλβουμινης ορου
AU2015286820A8 (en) Stabilization of poly(A) sequence encoding DNA sequences
EA201270758A1 (ru) Мутанты fgf21 и их применение
EA201171220A1 (ru) Мутанты fgf21 и их применение
SA522433360B1 (ar) L-أَسْباراجيناز مُعدل
WO2015051199A3 (en) Modified pseudomonas exotoxin a
PE20191248A1 (es) Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer
AR125394A2 (es) Métodos y composiciones para la expresión génica en plantas
EA201391632A1 (ru) Аминокислотные последовательности, направленные против il-17a, il-17f и/или il-17a/f, и содержащие их полипептиды
CY1113379T1 (el) Πεπτιδια κdr και εμβολια που τα περιλαμβανουν
WO2008140812A3 (en) Compositions and methods comprising klk3, psca, or folh1 antigen
AR076977A1 (es) Proteinas precursoras repetitivas autoensambladas
SI3191511T1 (en) Improved TNF binders
EA201100071A1 (ru) Новые композиции и способы
EA201891141A1 (ru) Новые антиангиогенные слитые полипептиды
PE20181897A1 (es) Inmunoterapia contra el melanoma y otros tipos de cancer
WO2016130628A8 (en) Griffithsin mutants
EP4269562A3 (en) Antigen binding molecules and methods of use thereof
EA202191651A1 (ru) Бициклические пептидные лиганды, специфичные к mt1-mmp
PE20230343A1 (es) Peptidos que estimulan respuestas inmunitarias antitumorales
PH12018550180A1 (en) Trispecific antibodies against il-17a, il-17f and another proinflammatory molecule